Trial Profile
LOW-DOSE METRONOMIC TEMOZOLOMIDE AND SORAFENIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME: A PHASE II CLINICAL TRIAL WITH EVALUATION OF CLINICAL, BIOLOGIC AND PHARMACODYNAMIC EFFECTS OF THE COMBINATION
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2013
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms GLIMESOR
- 29 Aug 2012 New trial record